Allogeneic stem cell transplantation following reduced-intensity conditioning is being evaluated in patients with advanced B-cell chronic lymphocytic leukemia (B-CLL). The curative potential of this procedure is mediated by donor-derived alloreactive T cells, resulting in a graft-versus-leukemia effect. However, B-CLL may escape T-cell-mediated immune reactivity since these cells lack expression of costimulatory molecules. We examined the most optimal method to transform B-CLL cells into efficient antigen-presenting cells (APC) using activating cytokines, by triggering toll-like receptors (TLRs) using microbial pathogens and by CD40 stimulation with CD40L-transfected fibroblasts. CD40 activation in the presence of IL-4 induced strongest upregulation of costimulatory and adhesion molecules on B-CLL cells and induced the production of high amounts of IL-12 by the leukemic cells. In contrast to primary B-CLL cells as stimulator cells, these malignant APCs were capable of inducing the generation of B-CLL-reactive CD8 þ CTL lines and clones from HLA class I-matched donors. These CTL lines and clones recognized and killed primary B-CLL as well as patient-derived lymphoblasts, but not donor cells. These results show the feasibility of ex vivo generation of B-CLL-reactive CD8 þ CTLs. This opens new perspectives for adoptive immunotherapy, following allogeneic stem cell transplantation in patients with advanced B-CLL.
Introduction
Chronic lymphocytic leukemia of B-cell origin (B-CLL) cannot be cured with conventional chemotherapy. 1 Although novel chemotherapeutic agents including purine analogues 2 and targeted therapy with monoclonal antibodies (MoAb) like alemtuzumab or anti-CD20 [3] [4] [5] are promising, these treatment modalities rarely lead to cure of the disease. Autologous stem cell transplantation (SCT) did not result in longer relapse-free survival than conventional therapies. 6 Allogeneic SCT is increasingly considered for treatment of patients with advanced B-CLL. The rationale for allogeneic SCT relies on adoptive transfer of donor-derived alloreactive T cells that may eradicate refractory or recurrent B-CLL. Complete sustained remissions in B-CLL patients have been observed after allogeneic SCT, suggesting a susceptibility of B-CLL cells to a graft-versusleukemia (GVL) effect. 6, 7 However, the application of allogeneic SCT in B-CLL has been hampered by high treatmentrelated mortality (TRM) in this extensively pretreated older patient population. 6, 7 Nonmyeloablative conditioning regimens may reduce short-term TRM. [8] [9] [10] Long-term follow-up of B-CLL patients treated with allogeneic SCT after dose-reduced conditioning regimens is limited, but short-term follow-up showed reduction of TRM with preservation of GVL reactivity. [7] [8] [9] [10] Acute or chronic graft-versus-host disease (GVHD) remains a major cause of morbidity and mortality. 7, 11 An approach to reduce GVHD reactivity while conserving GVL activity is to perform allogeneic SCT with in vitro T-cell depletion followed by treatment using in vitro-selected cytotoxic T lymphocytes (CTLs) with relative specificity for the B-CLL or using hematopoiesisrestricted minor histocompatibility antigen (mHag)-specific CTLs. 10, 12 Although B-CLL cells show high expression of HLA class I and II molecules necessary for presentation of antigens to T cells, B-CLL cells are unable to stimulate normal allogeneic T cells in a mixed lymphocyte reaction (MLR) due to inadequate expression of costimulatory and adhesion molecules. [13] [14] [15] For the induction of a sustained T-cell response, the expression of the costimulatory molecules CD80 or CD86 on the antigen-presenting cells (APC) is essential. 16 Both normal B cells and B-CLL cells highly express CD40, and stimulation of these cells via the CD40-CD40L pathway may enhance the immunogenicity of these cells by upregulating costimulatory molecules. 13, [17] [18] [19] [20] Hence, CD40-activated B-CLL cells may induce specific T-cell responses capable of reacting with leukemic cells. 13, 18, 21 Modification of B cells, monocytes or immature DC into efficient APCs can also be initiated by microbial products such as endotoxin (LPS), viral double-stranded RNA or immunostimulatory bacterial CpG-DNA sequences (CpG). [22] [23] [24] These microbial pathogens can be recognized by distinct toll-like receptors (TLRs) expressed on APC. Signaling through TLRs strongly activates APC to upregulate costimulatory molecules and to synthesize and release inflammatory cytokines. 24 Normal and neoplastic B cells express most TLRs at low or undectable levels except TLR9 and TLR10, which are abundantly expressed in B cells. 25, 26 Unmethylated CpG motifs, characteristic of bacterial DNA, are detected by TLR9, and may therefore stimulate normal and malignant B cells. [25] [26] [27] In this study, we investigated the most optimal method to modify B-CLL cells into efficient malignant APCs using several proinflammatory cytokines including interleukin (IL)-1, IFN-a and TNF-a, and cytokines IL-2, IL-3 and IL-4, known to upregulate costimulatory molecules in plasmacytoid dendritic cells (DC) and B-cells. [28] [29] [30] We further tested whether activation of TLRs by various microbial pathogens or triggering CD40 with CD40L-transfected fibroblasts could induce further upregulation of costimulatory molecules. Moreover, the additional stimulatory effects of TLRs triggering by microbial products on CD40-activated B-CLL cells was studied. To examine the potential use of in vitro-manipulated B-CLL for adoptive immunotherapy after allogeneic SCT, we used the modified B-CLL cells as APCs to generate allogeneic B-CLL-reactive CD8 þ CTL lines and clones from HLA class I-matched donors. Stimulation of CD40 on B-CLL cells in the presence of IL-4 induced the strongest upregulation of costimulatory molecules. Using these malignant APCs as stimulator cells, B-CLL-reactive CD8 þ CTL lines and clones were generated from three HLA class I-matched donors. These CTL lines and clones recognized and killed primary B-CLL as well as PHA blasts or EBV-transformed B cells (EBV-LCL) from the patient, but not donor-specific cells. Our findings indicate that ex vivo generation of B-CLL-reactive CD8
þ CTL lines and clones from HLA class I-matched donors is feasible.
Material and methods

Cell samples
After informed consent, peripheral blood samples were obtained from 14 untreated patients with B-CLL and from three healthy donors. Peripheral blood mononuclear cells (PBMC) of B-CLL patients were isolated from blood samples by Ficoll density separation and cryopreserved. As assessed by flow cytometry, more than 90% of the PBMC from B-CLL patients coexpressed CD19 and CD5 surface molecules. Three HLA class I-matched patient/donor pairs were used to induce a T-cell response against B-CLL cells. In two of the three patient/donor combinations, a one-locus HLA class II-mismatched donor was available. The HLA types of these patients and donors are shown in Table 1 .
Modification of B-CLL cells into APCs
B-CLL cells were cultured in IMDM (BioWhittaker, Verviers, Belgium) containing 10% human serum at 371C in a 5% CO 2 humified atmosphere in 24-well plates (Costar, Cambridge, MA, USA) at a concentration of 10 6 cells/well in a total volume of 1 ml/well. Leukemic cells were cultured in the presence or absence of the cytokines IL-1a (10 ng/ml, Hoffmann-La Roche, NJ, USA), IL-2 (100 U/ml, Chiron, Amsterdam, Netherlands), IL-3 (50 ng/ml, Novartis, Basel, Switzerland), IL-4 (500 U/ml, Schering-Plough, Amsterdam, the Netherlands), TNF-a (10 ng/ ml, Boehringer Ingelheim, Ingelheim am Rhein, Germany) or interferon-a (IFN-a, 1000 U/ml, Hoffmann-La Roche), or in the presence or absence of the cytokine combinations IL-3 and IL-4, IL-4 and IFN-a, or IL-4 and TNF-a. For activation of innate immunity, B-CLL cells were incubated with synthetic CpG oligodeoxynucleotide 2006 (CpG; 5 0 TCGTCGTTTTGTCG-TTTTGTCGTT-3 0 , 10mg/ml; Eurogentec, Seraing, Belgium), lipopolysaccheride (LPS, 100 ng/ml, Sigma-Aldrich, St Louis, MO, USA) or polyriboinosinic polyribocytidylic acid (Poly(I:C), 50 mg/ml, Sigma-Aldrich) in the presence or absence of IL-4 (500 U/ml). Finally, to enhance further upregulation of costimulatory molecules, B-CLL were cocultured on ltk murine fibroblast cells transfected with the human CD40-ligand 
Immunophenotyping and cytokine measurement
To perform immunophenotyping, mouse MoAbs conjugated with fluorescein isothiocyanate (FITC), phycoerythrin (PE) or phycoerythrin cyanine 5 (PE-Cy5) were used. These MoAbs included FITC-conjugated IgG1 antibodies specific for CD5, CD25, CD40, CD54 or CD86, and FITC-conjugated IgG2a antibodies specific for CD58 or HLA-DR. PE-conjugated IgG1 antibodies specific for CD14, CD19, CD23, CD56, CD80 or CD123, PE-conjugated IgG2a antibodies specific for CD8, PEconjugated IgG2b antibodies specific for CD83, and PE-Cy5-conjugated IgG1 antibodies specific for CD3 were used. Appropriate isotype controls (IgG1, IgG2a and IgG2b) were used. All MoAbs were purchased from Becton Dickinson (BD, San Jose, CA, USA) except for anti-CD40 and anti-CD58 (Serotec, Oxford, England), anti-CD54 (CLB, Amsterdam, the Netherlands), anti-CD8 and anti-CD83 (Caltag, Burlingame, AL, USA) and anti-CD80 (Immunotech, Marseille, France). A total of 10 5 cells were incubated with MoAbs for 30 min at 41C, washed twice, and analyzed on a FACScan (BD). Results were analyzed using the CellQuest software (BD). The relative expression of surface antigen is described as the mean fluorescence intensity ratio (MFIR). This value is calculated by dividing MFI of cells stained with a specific MoAbs by the MFI of cells stained with an isotype-control MoAbs. If the percentage of positive events was more than 10%, the leukemic sample was considered positive for that surface marker, and then the MFIR was calculated. Cellfree supernatants were harvested after 96 h of culturing the B-CLL cells with or without cytokines, microbial pathogens and tCD40L cells. Cytokine measurements were performed using commercial IL-10 (CLB) or IL-12 p40/p70 (U-CyTech, Utrecht, the Netherlands), ELISA kits according to the manufacturer's instructions. Table 1 HLA type of donor and patients
a Donor-patient disparate alleles. HLA-A, -B, and -C typing was performed by standard serology methods, and HLA-DR and -DQ typing was performed by DNA analysis using sequence-specific primers.
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Generation of B-CLL-reactive CTL lines and clones
PBMC from unrelated healthy HLA class I-matched donors (Table 1 ) at a concentration of 0.5 Â 10 6 cell/well in 24-well plates (Costar) were stimulated with irradiated primary B-CLL, or B-CLL cells cultured under various conditions at a responder/ stimulator (R/S) ratio of 10:1. IL-2 (100 IU/ml) was added at day 6, and 2 days after each (re)stimulation. At day 9, the T cells lines were harvested, and depleted of CD4 þ T cells using anti-CD4-conjugated magnetic beads (Milteny Biotec, Bergisch Gladbach, Germany). The T-cell lines were restimulated with irradiated stimulator cells at the same R/S ratios at days 9, 16 and 23. T cells were harvested 4-5 days after the third or fourth stimulation for phenotypic analysis, and used as effectors in cytotoxicity assays. T-cell clones were generated from B-CLLreactive Cr-release assay.
Cytotoxicity assay
51 Cr-release assays were performed as described previously. 32 Briefly, primary B-CLL cells, or B-CLL cells cultured under various conditions, EBV-LCL or PHA blasts from patient or donor were used as target cells. Effector cells and 5000 51 Cr-labeled target cells were added to wells of U-bottom microtiter plates at E/T ratio's ranging from 30:1 to 1:1. Spontaneous release was measured by addition of 100 ml IMDM with 10% human serum, and maximum release by adding 100 ml 1% Triton X-solution to target cells. After 4 h of incubation at 371C, 51 Cr release was measured in a luminescence counter (Topcount-NXT, Packard, Meriden, CT, USA). The percentage lysis was calculated using the following formula: 100 Â ((experimental release cpmÀspon-spontaneous release cpm)/(maximum release cpmÀspontaneous release cpm)). T-cell lines and clones showing more than 10% specific lysis of target cells were considered cytotoxic. To determine HLA class I and II restriction of the recognition of the target cells, blocking studies were performed in selected experiments. Target cells were incubated with anti-HLA class I antibodies (W6/32) or anti-HLA class II antibodies (PdV5.2, kindly provided by Dr A Mulder, Department of Immunohematology and Bloodtransfusion, Leiden) at final concentrations of 10 mg/ml for 30 min before effector cells added. Blocking experiments at effector level were performed by adding anti-CD8 MoAb (FK18, RIVM, Bilthoven, the Netherlands) at a final dilution of 8 mg/ml, 30 min prior addition of target cells.
Statistical analysis
Differences between experimental groups were analyzed using the Student's t-test.
Results
Upregulation of costimulatory and adhesion molecules on B-CLL cells
Cell surface expression of adhesion molecules CD54 and CD58, and costimulatory molecules CD40, CD80, CD86 and CD83 on freshly isolated B-CLL cells are shown in Table 2 . All patients showed intermediate (MFIR 20-50) or high expression (MFIR 450) of HLA class I and II. CD58 was expressed at low levels (MFIR o20) in all patients. CD54 expression was negative in three patients and low or intermediate in the other patients. CD40 was expressed at intermediate levels in all patients. In only five patients expression of CD80 and/or CD86 was observed.
To upregulate the expression of adhesion and costimulatory molecules on B-CLL cells, we first tested several cytokines, To determine the optimal time period of CD40 and IL-4 stimulation, phenotypic analysis of B-CLL cells was performed 48, 96 and 144 h after stimulation. As shown in Figure 2 , IL-4 and CD40 activation of B-CLL cells caused strong upregulation Figure 1 Expression and upregulation of costimulatory and adhesion molecules on B-CLL cells activated by IL-4, CpG and/or tCD40L (a) Combinations using CD40 activation give significant higher percentages of positive B-CLL cells for CD80, CD85, CD54 and CD83 (Po0.01) (b) CD40 activation of B-CLL cells caused significant upregulation of expression levels of all costimulatory and adhesion molecules (Po0.001) and the addition of IL-4 further enhanced the expression levels of CD80 and CD86 (P ¼ 0.05 and P ¼ 0.14, respectively). B-CLL cells were cultured for 96 h in the presence or absence of IL-4 (500 UI/ml), CpG (10 mg/ml) and/or tCD40L. Expression of CD80, CD86, CD54 and CD83 was analyzed by flow cytometry. The MFIR was calculated as described in Material and methods section, only if percentage of positive cells was 410%. Results are expressed as mean7s.d. of number of B-CLL patients as shown in figure. B-CLL-reactive T-cell lines and clones M Hoogendoorn et al of CD80, CD86, CD83 and CD54 within 48 h. After 96 h of stimulation, a further enhancement of expression levels of CD80 (MFIR 1.2-fold, P ¼ 0.07) and CD86 (MFIR 1.4, P ¼ 0.05) was observed. However, after 48 h, a significant downregulation of percentages and expression levels of CD83 were found (Po0.05). Therefore, we considered activation of the B-CLL cells with tCD40L and IL-4 to be optimal after 96 h.
Stimulation of tCD40L induced a dendritic-like morphology in 60-80% of the B-CLL cells and as determined by forward/ sideward analysis using flow cytometry, a 2-3-fold increase in size of CD40-activated B-CLL cells was seen (data not shown). Recovery of viable B-CLL cells after 96 h was 29711% (mean7s.d.) for B-CLL cells cultured in medium alone. Enhanced survival of 45712% was found when B-CLL cells were cultured on tCD40L in medium containing IL-4. In conclusion, stimulation of B-CLL cells by tCD40L and IL-4 for a period of 96 h caused the strongest upregulation of costimulatory and adhesion molecules and modified B-CLL cells into morphologically and phenotypically characteristic APC.
Production of IL-10 and IL-12 by activated B-CLL cells
As demonstrated in Figure 3 , after 96 h of culture, primary B-CLL cells and CpG/IL-4 activated B-CLL cells produced only minimal amounts of IL-12 (65722 and 50727 pg/ml, respectively, n ¼ 7, mean7s.d.). However, significant higher levels of IL-12 were produced by tCD40L-activated B-CLL cells (253972301 pg/ml, P ¼ 0.005, n ¼ 6). Additional stimulation with IL-4 or CpG further enhanced the production of IL-12 to 795373980 pg/ml (n ¼ 7) and 563273310 pg/ml (n ¼ 5) respectively. In all conditions, only low amounts of IL-10 were produced (o20 pg/ml). Table 1 ) were stimulated with the three types of stimulator cells. Since donors were HLA class II mismatched, CD4 depletion was performed to eliminate undesirable allo-HLA responses. The growth kinetics of the CD8 þ T cells in response to the different stimulator cells are shown in Figure 5 . No proliferation of donor T cells was seen using primary B-CLL as stimulator cells. Using CpG/IL-4-activated B-CLL cells as stimulators, in two of the three patient/donor pairs limited proliferation of CD8 þ T cells was observed. In contrast, using tCD40L/IL-4-activated B-CLL cells as APCs in all three patient/ donor combinations tested, a 12-15-fold increase of CD8 þ T cells was observed.
The cytotoxic activity of the CTL lines was tested using primary B-CLL, tCD40L/IL-4-activated B-CLL cells, PHA blasts or EBV-LCL from patients and donors as target cells. In all three tested patient/donor pairs, CTL lines, generated in response to tCD40L/IL-4-activated B-CLL cells as stimulators, effectively killed at E/T ratios of 30:1, the primary B-CLL (41.1724.7%, mean7s.d., n ¼ 3), the tCD40L/IL-4-activated B-CLL cells (46.3726.2%) and PHA blasts or EBV-LCL of patients (52.8710.8%) in a 4-h 51 Cr release assay. In contrast, PHA blasts or EBV-LCL from the donor were not killed (4.373.0%, n ¼ 3). Cytotoxicity of the generated CTLs is shown in Figure 6 . In only one of the three donor/patients pairs, cytotoxicity of a CTL line generated using CpG/IL-4-activated B-CLL cells as APCs could be tested, illustrating cytotoxicity to the B-CLLspecific targets and PHA blasts from the patient as shown in Figure 6a2 . In summary, in contrast to primary B-CLL cells, tCD40L/IL-4-activated B-CLL cells can be used as stimulator cells to generate CTL lines recognizing and killing B-CLLspecific targets and PHA blasts or EBV-LCL from the patients. To exclude HLA-nonrestricted killing and to exclude that the cytotoxicy of the CTL lines was exerted by allo-HLA-driven contaminating CD4 þ T cells, blocking studies were performed using a representative example of a generated B-CLL-reactive CTL line. Cytoxicity was completely blocked by anti-HLA class I or anti-CD8 antibodies and not by the addition of anti-HLA class II (Figure 6d ). These results confirmed HLA class I-restricted recognition of the targets by the CD8 þ CTL lines.
Generation of B-CLL-reactive CTL clones
To determine whether the cytotoxicity of the generated CTL lines was exerted by cytotoxic T cells with different specificity, anti-B-CLL CTL line was sorted one cell per well, at day 23. A and PHA blasts from the patient (42.3719.0%) and not PHA blasts from the donor (3.071.5%), when tested at an E/T ratio of 10:1 ( Figure 7) . The other six clones showed antigen-driven proliferation, but were not cytotoxic to B-CLL-specific targets (data not shown).
Discussion
The aim of this study was to investigate the best method to modify B-CLL cells into malignant APCs and to test their capacity to activate allogeneic T cells to generate B-CLLreactive T-cell reponses. CD40 activation, in the presence of IL-4, was shown to most effectively transform B-CLL cells into efficient APCs, capable of producing high amounts of IL-12. In all three HLA class I identical donor/patient pairs tested, using these malignant APC as stimulator cells, allogeneic CD8
þ T-cell lines were generated, recognizing B-CLL as well as patientderived PHA blasts. Cloning of these B-CLL-reactive T-cell responses revealed that single CTL clones recognized both nonmalignant patient-derived and B-CLL-specific targets.
Primary B-CLL cells have previously been demonstrated to be unable to stimulate donor T-cell proliferation and activation. This has been explained by the inadequate expression of costimulatory and adhesion molecules. 13, 18, 21, 33 CD40 ligation has been shown to be an effective tool to upregulate costimulatory molecules on the surface on B-CLL cells. 13, 17, 18, 21, 33 CD40-triggered B-CLL cells, as stimulator cells, can activate allogeneic T cells in MLRs and can induce allogeneic immune responses against B-CLL cells. 13, 15, 18, 21, 33, 34 In attempts to improve the immunogenicity of B-CLL cells without using the CD40 system, we investigated several alternatives. We first explored the ability of several cytokines to upregulate costimulatory molecules. The proinflammatory cytokines, proliferating cytokines, plasmacytoid-DC stimulatory did not cause significant upregulation of costimulatory molecules. Recent studies have demonstrated that normal, but also malignant B cells, express a distinct TLR expression profile in which TLR9 and TLR10 predominate. 25, 26, 36, 37 We therefore tested triggering of TLRs on B-CLL cells and showed that CpG, agonist of TLR 9, in combination with IL-4, increased the expression of costimulatory molecules.
However, CD40 activation significantly further enhanced the expression levels of all costimulatory and adhesion molecules and was superior to all combinations tested without CD40 ligation. The addition of IL-4 further enhanced the expression of CD80 and CD86, thus confirming results from other studies. 13, 17, 18, 21, 33 Although CD40 activation can upregulate the expression levels of TLR9 in B cells and can increase the responsiveness to CpG, 25, 26 no additional upregulating effect but rather a downregulating effect was observed by adding CpG.
Professional APCs can express and secrete IL-12 after challenge with microbial stimuli or after CD40L-CD40 interactions between T cells and the APCs. 38 IL-12 is a pivotal cytokine in the Th1-response to antigen and its effect includes enhanced CTL activity of CD8 þ T cells and natural killer cells, and further differentation of antigen-activated CD4 þ and CD8 þ T cells. 39 We demonstrated that CD40 activation is essential for the IL-12 production by B-CLL cells and showed that additional activation using CpG or IL-4 resulted in a higher IL-12 production. These results are in accordance with studies showing that CD40 activation induced enhanced IL-12 mRNA expression in normal and neoplastic B lymphocytes, including follicular lymphoma and mariginal zone lymphoma cells, resulting in IL-12 secretion by these B cells. 40, 41 In summary, the CD40-CD40L pathway is critical to modify B-CLL cells into phenotypically professional APC, capable of producing significant amounts of IL-12. Cytokines and/or microbial pathogens are insufficient to stimulate B-CLL cells.
Expression of adhesion and costimulatory molecules on APCs is necessary to induce efficient T-cell responses. We confirmed that T cells demonstrate very low proliferative responses upon restimulation with unmodified B-CLL cells. Since CpG/IL-4-activated B-CLL cells could be generated under good manifacturing practice (GMP) conditions, we analyzed whether the minimal upregulation of costimulatory molecules on CpG/IL-4-acitvated B-CLL cells was sufficient to overcome T-cell anergy. In two of three HLA class I-matched combinations proliferation and in one of the three couples tested, cytotoxicity against B-CLL-and patient-derived targets of CD8 þ CTL lines using these APCs was obtained. Although our results extend reports from others, 34 only very limited proliferation of donor T cells in response to CpG/IL-4-activated B-CLL cells was observed ( Figure 5 ), and the generation of a B-CLL-reactive CTL line was successful in only one of the three donors tested.
The importance of high expression of costimulatory molecules on APCs was demonstrated by the capacity of tCD40L/IL-4-activated B-CLL cells to induce vigorous expansion of B-CLL-reactive CD8 þ CTL lines. We were able to generate CD8 þ CTL lines from HLA class I-matched donors with high cytotoxic activity against primary and modified B-CLL cells. Moreover, using one cell/well sorting, several B-CLL-reactive proliferating CD8
þ CTL clones from a HLA class I-matched donor could be obtained, illustrating that the cytotoxicity could not be due to contaminating allo-HLA class II CD4 responses. Furthermore, the cytotoxicity of the generated CD8 þ CTL lines was completely abrogated by anti-HLA class I antibodies and not by anti-HLA class II antibodies.
In conclusion, this study not only demonstrates that CD40-activated B-CLL cells have the stimulatory capacity to induce an alloresponse over a MHC barrier, but more importantly it shows the feasibility to generate CD8 þ CTL lines and clones from HLA class I-matched donors, recognizing leukemia-specific as well as nonmalignant patient-derived targets. These results suggest Cytotoxicity of the four donor-derived CD8 þ CTL clones. CTL clones were generated in donor/CLL 3 combination by one cell/well sorting of the donor-derived CTL line at day 23. At day 0 and 14, the T cell was stimulated with irradiated tCD40L/IL-4-activated B-CLL cells and allogeneic feeder cells in medium with IL-2 and PHA. Proliferating clones were tested in a 51Cr release assay against primary B-CLL, tCD40L/IL-4-activated B-CLL and PHA blasts from patient and donor at day 21.
B-CLL-reactive T-cell lines and clones M Hoogendoorn et al that the antigens recognized by the CTL lines and clones are not B-CLL tumor specific but rather mHag specific. 18, 21, 33, 34 Whether the mHags, recognized by the CTL lines and clones are hematopoiesis-restricted and/or B-cell specific remains to be elucidated.
